Articles tagged with Drug Studies
The E1910 trial found that adding blinatumomab to standard front-line consolidation chemotherapy improved overall survival and kept most patients in remission. The treatment, which targets malignant B cells, demonstrated its effectiveness in patients with a good prognosis after an initial round of chemotherapy.
Researchers at Baylor College of Medicine have identified a potential new treatment for endometriosis, oleuropein, which selectively inhibits ER-beta activity. This natural compound effectively suppresses the growth of endometriosis lesions in mouse models and improves fertility in mice with endometriosis.
A new study published in JAMA Network Open found that patients with depression are less likely to adhere to essential medical therapies following percutaneous coronary intervention (PCI). The study examined over 124,000 patients who underwent PCI and were diagnosed with depression, revealing a significant proportion of individuals with...
A large observational study found that Paxlovid is associated with a 44% reduction in hospitalization or death among highly vaccinated adults over 50. Even among patients with lower levels of prior immunity, Paxlovid showed an 81% reduction in hospitalization rates.
A randomized controlled trial found that a low-carbohydrate, high-fat diet helped patients with type 2 diabetes achieve better weight loss and glucose control over a 6-month intervention compared to a high-carb, low-fat diet. However, changes were not sustained 3 months after the intervention.
A new American Heart Association scientific statement highlights the potential benefits and risks of complementary and alternative therapies for heart failure. The statement advises healthcare professionals to discuss CAM use with patients, monitor medication interactions, and consider pharmacists' consultations.
A new study has shed light on how the most commonly used ADHD medication, methylphenidate, works in the brain. The research found that methylphenidate increases dopamine levels in the nucleus accumbens and improves coordinated brain network activity, resulting in more stable sustained attention in children with ADHD.
Researchers found that activating the non-mutated form of P53 can change the fundamental makeup of cancer stem cells in mouse models of mucoepidermoid carcinoma. This new therapy approach shows promise for treating this lethal form of salivary gland cancer.
A new study allows people with type 2 diabetes to choose their own medication after trying three different drugs in succession. The approach resulted in better glucose control and fewer side effects compared to other methods. Researchers conclude that patients should try before choosing a treatment for optimal results.
The phase 1 and phase 2 studies showed that ARV-471 was well-tolerated and could promote substantial estrogen receptor degradation in patients with advanced disease. The study has led to a randomized phase 3 trial comparing ARV-471 with a SERD in patients with ER-positive/HER2-negative advanced breast cancer.
A study published in the Hypertension journal suggests that bromocriptine, a Parkinson's disease medication, may help prevent heart disease in youth with Type 1 diabetes. The research found that teens with Type 1 diabetes who took bromocriptine had lower blood pressure and less stiff arteries after one month of treatment.
A new antimalarial drug, tafenoquine, is found to require a higher dose of 450mg to achieve cure rates of 85% compared to the current 300mg dose of 70%. The study suggests that the single-dose tafenoquine is not as effective as optimal primaquine treatment in preventing vivax malaria relapses in all endemic regions.
A study published in Tobacco Control found that alternatives to menthol cigarettes pose significant addiction and health risks. Mentholated pipe tobacco and tubes were the most appealing and addictive options, suggesting they should be included in the proposed ban.
A study of over one million Medicaid beneficiaries found that more than half experienced significant lapses in coverage, with only 25% continuously enrolled throughout the period. The authors recommend increasing investments to improve long-term health outcomes.
A new 16-week trial will test whether a medication that targets gut bacteria can improve irritability in teenagers with autism spectrum disorder. The study aims to reduce the entry of certain substances produced by gut bacteria into the brain via the bloodstream, potentially reducing traits of irritability and anxiety.
Researchers found that the NIH Toolbox Cognition Battery is a promising option for measuring cognitive change in people with intellectual disability. The study shows that the test is sensitive to developmental changes in children, teens, and young adults, which can help guide effective interventions.
Researchers used mass spectrometry to analyze complex biological samples, including Salvia miltiorrhiza Bge and Astragali Radix. The studies identified metabolites and compounds with immunoregulatory effects, highlighting the potential for new drugs and improving plant quality.
A new study pinpoints the first-ever domestication of cats to nearly 10,000 years ago in the Fertile Crescent region. Genetic analysis reveals that humans' transition from hunter-gatherers to farmers sparked the bond between humans and rodents-eating cats, leading to their migration with humans worldwide.
A Mount Sinai study found that certain inflammatory markers can predict which patients are more likely to respond to COVID-19 immunotherapies. The researchers identified a subtype of COVID-19 patients with hyperinflammation who could benefit from pacritinib, an anti-cancer drug.
The Phase II/III study found that acoziborole has an 18-month treatment success rate of 95% for late-stage patients and 100% for early-stage patients, with no significant safety concerns reported. This breakthrough could lead to the elimination of sleeping sickness through a simplified 'screen-and-treat' approach.
A survey by UCI MIND found that media coverage of the FDA's decision made people less willing to volunteer for Alzheimer's pharmaceutical trials. The study highlights the powerful influence of media coverage on scientific research and emphasizes the need for diverse populations in clinical trials.
A study found that concerns about colonoscopy, lack of opportunity to discuss next steps with a medical provider, and assumptions about personal risk are common reasons patients don't follow up after a positive at-home test. Researchers also developed two simple risk measurement tools to predict COVID-19 mortality rates, which could he...
Researchers found that buprenorphine use was associated with better outcomes for the baby, including lower risk of preterm birth, small size for gestational age, and low birth weight. The study suggests increasing access to buprenorphine treatment among pregnant individuals with opioid-use disorder.
A pilot study found that nearly half of patients treated with aflibercept could safely stop eye injections without vision loss, while only 17% of those on bevacizumab were able to do so. The findings suggest that matching patients with the right therapy may reduce the need for lifelong treatment.
A Johns Hopkins Medicine study found that pregnant women taking Paxlovid had a reduced risk of severe COVID-19. The research, published in JAMA Network Open, included 47 participants who received Paxlovid therapy and monitored for outcomes and complications.
A new study found that a single dose of acoziborole is as effective as current treatments for sleeping sickness, with a cure rate of 95% for late-stage patients and 100% for early/intermediate-stage patients. The treatment could revolutionize treatment for the disease by eliminating barriers such as hospitalization and travel distances.
A study of over 1,000 healthcare workers found that medical masks may be as effective as N95 respirators in preventing COVID-19 infection. However, the results varied across countries and were influenced by factors such as vaccine use and variant circulating during the pandemic.
A new study by Rutgers researchers found that young people treated for sleep disorders with benzodiazepines like Xanax may be at a higher risk of overdose. The study examined over 90,000 newly prescribed benzodiazepine patients and found an increased risk of overdose compared to other prescription sleep medications.
Researchers found that individuals with persistent asthma have higher levels of inflammation and artery plaque, which may increase heart attack or stroke risk. The study also highlights the importance of addressing risk factors for cardiovascular disease in people with persistent asthma.
A new study from Northwestern University found that vitamin D supplements do not significantly reduce statin-associated muscle symptoms, contradicting previous non-randomized studies. The trial involved 2,083 participants and was the first placebo-controlled, randomized clinical trial to examine this effect.
A systematic review and meta-analysis of ADC clinical trials found that 91.2% of patients experienced treatment-related adverse events, with serious side effects including neutropenia, hypoesthesia, and thrombocytopenia. The study highlights the need for clinicians to address these toxicities in ADCs' use.
A pooled data analysis of 10 randomized controlled trials involving 1040 women found that acupuncture significantly relieved pain during pregnancy, improved physical function, and quality of life. The therapy was also found to be safe, with no observable major side effects for newborns.
A researcher at Ohio University is using a $1.4 million grant from the National Institute on Drug Abuse to develop a training program for healthcare professionals to overcome stigma surrounding Buprenorphine prescriptions. The study aims to increase access to harm reduction services in rural areas.
Researchers at University Hospitals and Case Western Reserve University have discovered a small-molecule oral drug that reduces PCSK9 levels and lowers cholesterol by 70% in animal models. This breakthrough could also improve the efficacy of cancer immunotherapies.
Researchers demonstrate a new way to deliver medication to malignant brain tumors in mice, using a modified peptide that can penetrate the blood-brain barrier. The study shows promising results, with a 50% increase in survival rate for treated mice, and offers hope for future treatment breakthroughs.
A study published in PLOS ONE found that adults with type 2 diabetes taking metformin had a 45% lower risk of needing a breathing machine or dying from COVID-19 compared to those not taking the medication. The research team analyzed data from a large database and suggested metformin may be an effective treatment option for reducing COV...
The FDA approved Aduhelm for Alzheimer's treatment based on reduced amyloid levels in the brain, despite no significant clinical effect. The use of amyloid-PET scans is being questioned for its accuracy and reliability in measuring amyloid removal.
Studies found that sotrovimab reduced the risk of severe covid-19 outcomes by 46% compared to molnupiravir. However, no benefit was found for common heart drugs like ARBs in a randomised controlled trial.
The FDA's investigation into its own oversight of clinical trials reveals a concerning lack of surveillance, leaving room for scientific misconduct. Experts argue that the agency should inspect sites more frequently to ensure data quality and integrity.
A large registry-based study found lisdexamfetamine to be associated with the lowest risk of hospitalisation and death in people with amphetamine addiction. The medication showed a significant reduction in hospitalisation due to substance use disorder and any cause or death, while benzodiazepine and antidepressant use were linked to po...
A new prodrug called DRP-104 targets cancer cells' high demand for glutamine, eliminating them while sparing healthy tissues. The drug is in early-stage clinical trials for advanced solid tumors and shows promise as a safer alternative to existing treatments.
Researchers have identified potential new lead compounds for treating depression and anxiety disorders, which display reduced risk of drug abuse and adverse effects. These substances, derived from synthetic cathinone compounds, are known to release serotonin without significantly increasing dopamine levels in the brain.
A research team developed a vaccine targeting synthetic opioid fentanyl to block its entry into the brain, preventing fatal effects. The breakthrough could have major implications for treating Opioid Use Disorder, with potential relapse prevention capabilities.
A study by Okayama University researchers found that neuromedin U (NMU) is involved in metabolic processes but its 'anti-hunger' function may not be crucial for rats. Unlike mice, NMU expression is restricted in the rat brain and does not suppress feeding behavior.
The study aims to assess the effectiveness of recombinant Factor VIIa (rFVIIa) in decreasing bleeding in the brain of patients with intracerebral hemorrhage (ICH). ICH is a deadly stroke type with no effective treatment, and this trial seeks to improve outcomes.
Researchers at the University of Helsinki have identified a promising drug candidate, TYK2 inhibitor, for preventing type 1 diabetes. The study found that inhibiting TYK2 expression reduces the destruction of pancreatic beta cells, but may also reduce beta cell production in earlier stages.
The West Texas Pharmacology Core laboratory at TTUHSC will focus on two primary areas: drug development and pediatric cancer. The core aims to address obstacles in drug development, including limited pharmacology expertise for small biotech companies and low profitability for pediatric cancer drugs.
A UK Biobank study found that people with hypertension have a 22% higher chance of developing severe COVID-19. Successfully managing blood pressure through medication can significantly lower this risk. The study analyzed data from over 16,000 infected individuals.
Researchers have discovered two novel drugs that can block the growth and shrink the size of schwannoma tumors, a type of nerve sheath tumor found in the nervous system. The treatment works by inhibiting the Hippo signaling pathway, which is dysregulated in multiple types of cancer.
Researchers believe that changes in the brain's orexin system promote drug-seeking behavior and that existing insomnia treatments could reduce or eliminate cravings. Studies have shown that blocking this system reverses addiction in animals and reduces opioid cravings in human subjects.
Researchers discovered stem cells in mouse dorsal root ganglia (DRG) with the potential to regenerate lost sensory neurons and glia. These cells, known as satellite glia, can become activated and generate new glia and, to a lesser extent, neurons after injury.
Researchers conducted the largest clinical trial to date of psilocybin, finding a statistically significant rapid reduction in symptoms of depression. The study suggests that COMP360 psilocybin with psychological support could be an effective treatment strategy for people with treatment-resistant depression.
A new study found that a personalized 'precision' testing approach for people with stable chest pain led to more efficient evaluations and improved diagnosis of coronary artery disease. The approach involved assessing cardiovascular risk factors to identify low-risk individuals who may not benefit from further testing.
A new study found that rapid optimization of oral heart failure medications reduced the risk of dying or being readmitted for heart failure within six months after discharge. The STRONG-HF trial enrolled over 1,000 people hospitalized for acute heart failure and showed significant improvement in outcomes with high-intensity care.
Regular use of cholesterol-lowering and diabetes-control drugs may lessen the risk of age-related macular degeneration (AMD) in European populations. The pooled data analysis involved 38,694 participants and showed a 15% lower prevalence of any type of AMD with these medications.
A randomized controlled trial found that oral ENT-01 significantly improves constipation and possibly neurological symptoms in persons with Parkinson disease. The treatment is safe for up to 25 days, with a dose-dependent effect that persists beyond the treatment period.
Researchers found that two common diuretics, chlorthalidone and hydrochlorothiazide, had no difference in cardiovascular outcomes among study participants. However, those taking chlorthalidone showed a reduced risk of heart disease and death by an average of 27% among patients with a history of heart attack or stroke.
A new medication, pemafibrate, lowered triglyceride levels among adults with Type 2 diabetes, but did not decrease their cardiovascular risk. The study found that lowering triglyceride levels may not protect against cardiovascular disease in people with Type 2 diabetes.
A study published in the American Heart Association found that six common dietary supplements did not lower LDL cholesterol levels when compared to a low-dose statin medication or placebo. The research suggests that these supplements are unlikely to offer meaningful impact on cholesterol levels, and a heart-healthy lifestyle is still t...
A new study found that long-term treatment with intravenous iron improved symptoms and reduced recurrent hospitalizations among people with heart failure and iron deficiency. The treatment was associated with a significant benefit on reducing the risk of heart failure hospitalization and cardiovascular death.